Outcomes of COVID-19 in Adult Males With Hemophilia A: A Propensity Score-Matched Analysis

Meric Mericliler 1,2, Gayatri Narayan 3

1. Hematology and Medical Oncology, Virginia Commonwealth University, Richmond, USA 2. Hematology and Medical Oncology, Massey Cancer Center, Richmond, USA 3. Internal Medicine, Saint Vincent Hospital, Worcester, USA

Abstract

Background

Hypercoagulability is a major pathologic event in COVID-19. Factor VIII plays an important role in hemostasis, and high levels of factor VIII have been shown to be associated with an increased risk of thrombosis and severe disease. Little is known about the impact of COVID-19 on clinical outcomes in patients with hemophilia A.

Methodology

Retrospective data of adult male patients with COVID-19 with and without hemophilia A were retrieved from the TriNetX database (Cambridge, USA). The 1:1 propensity score-matching was performed to balance baseline characteristics. Patients were matched for age, race, body mass index, and medical comorbidities. Thirty-day outcomes were assessed.

Results

We identified 1,758 patients with pre-existing hemophilia A diagnosis prior to COVID-19 diagnosis and 5,191,908 comparators. After 1:1 propensity score matching, groups were balanced on demographics and comorbidities. All-cause mortality rates were similar between the two groups (HR 0.805; 95% CI 0.467-1.389). The frequency of severe infection, ICU admission, and composite thrombotic events did not differ between the groups. Patients with hemophilia A were hospitalized more frequently than those without a history of hemophilia A (19.2% vs. 14.4%; p<0.05). Additionally, gastrointestinal (GI) bleeding and composite bleeding events occurred more frequently in patients with hemophilia A (3.2% vs. 2.2%; p<0.05 and 4.0% vs. 2.8%; p<0.05, respectively).

Conclusions

The mortality of individuals with hemophilia A due to COVID-19 is comparable to the general population but with higher risks of hospitalization and bleeding.

Introduction

Background

Hypercoagulability is one of the hallmark pathologic features of COVID-19, and COVID-19-associated coagulopathy (CAC) is an important cause of morbidity and mortality [1]. The exact mechanism of CAC remains elusive. Studies have shown that endothelial cell dysfunction, increased platelet activation, activation of the coagulation, and alterations in the fibrinolytic system may play an important role in the pathogenesis [2]. Elevated factor VIII activity is commonly observed in critically ill patients with COVID-19 [3,4]. Additionally, patients with COVID-19 have been shown to have higher factor VIII activity compared to control patients with non-SARS-CoV-2 pneumonia, suggesting inflammation may not be the sole factor contributing to the elevated factor VIII activity [5]. Elevated factor VIII activity is a predictor of severity and mortality in COVID-19 patients [6].

Little is known about the impact of COVID-19 on clinical outcomes in patients with bleeding disorders. Early observational studies argued that patients with congenital bleeding disorders (CBD) tend to have similar disease severity or even less severe disease compared to the rest of the population [7-9]. However, these studies were not comparative and included only a limited number of patients.
Objective
The aim of this study was to investigate the clinical outcomes of COVID-19 in patients with hemophilia A using a propensity score-matched analysis in a multi-institutional research network database.

Materials And Methods

Study design and setting
This was a multicenter retrospective cohort study, which assessed the outcomes of COVID-19 in patients with hemophilia A. Retrospective data of patients with COVID-19 with and without hemophilia A was retrieved from the TriNetX database (Cambridge, USA), a global health collaborative clinical research platform collecting anonymous data from the electronic medical records of 90 healthcare organizations. The TriNetX database has been previously described in the literature [10].

Participants
We identified two groups: (1) Males aged 18 years and older with hemophilia A who tested positive for SARS-CoV-2 and (2) Males aged 18 years and older without hemophilia A who tested positive for SARS-CoV-2. We included patients who tested positive for SARS-CoV-2 between December 1, 2020, and September 20, 2022. Cases were identified using relevant diagnostic codes. We excluded females, patients younger than 18 or older than 90 years of age, and those diagnosed with acquired coagulation factor deficiencies.

The study was exempt from institutional review board approval because we utilized deidentified patient records on the TriNetX platform.

Variables and outcome measures
The 1:1 propensity score matching was performed to balance baseline characteristics. Variables used in the propensity matching represent the established risk factors for severe COVID-19. Patients were matched for age, race, overweight/obesity, ischemic heart disease, cerebrovascular disease, peripheral vascular disease, heart failure, atrial fibrillation, venous thromboembolism, tobacco use disorder, alcohol-related disorders, liver disease, HIV infection, chronic lower respiratory disease, chronic kidney disease, hypertension, diabetes mellitus, and neoplasm.

The primary outcomes of our study included all-cause mortality, severe COVID-19 (composite outcome of ICU admission, mechanical ventilation, or death), and the composite of thrombotic events within 30 days after infection. The secondary outcomes included hospitalization, ICU admission, need for mechanical ventilation, need for renal replacement therapy, venous thromboembolism, ischemic stroke, myocardial infarction, intracranial hemorrhage (ICH), gastrointestinal bleeding, and the composite of intracerebral hemorrhage and gastrointestinal bleeding. All examined outcomes were assessed within 30 days after the COVID-19 diagnosis.

Outcomes were defined by using the appropriate Logical Observation Identifiers Names and Codes (LOINCs), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), Current Procedural Terminology (CPT), and National Drug File Reference Terminology (NDF-RT) codes. The details of the diagnosis and laboratory test codes for the outcome measures are described in Table 1.

### ICD-10

| Diagnosis                        | Code     |
|----------------------------------|----------|
| COVID-19                         | U07.1, U07.2 |
| Hereditary factor VIII deficiency | D66      |
| Acquired coagulation factor deficiency | D68.4   |
| Overweight and obesity           | E66      |
| Essential hypertension           | I10      |
| Alcohol related disorders        | F10      |
| Nicotine dependence              | F17      |
| Chronic kidney disease           | N18      |
| Ischemic heart diseases          | I20-I25  |
| Heart failure                    | I50      |
| Disorder/Condition                                  | Code(s)                           |
|----------------------------------------------------|-----------------------------------|
| Disorders of lipoprotein metabolism                | E78                               |
| Atrial fibrillation and flutter                    | I48                               |
| Peripheral vascular disease                        | I73                               |
| Diseases of liver                                  | K70-K77                           |
| Chronic lower respiratory diseases                 | J40-J47                           |
| Diabetes mellitus                                  | E08-E11                           |
| Arterial embolism and thrombosis                   | I74                               |
| Transient cerebral ischemic attack and related syndromes | G45                              |
| Cerebrovascular disease                            | I60-69                            |
| Neoplasm                                           | C00-D49                           |
| Chronic kidney disease                             | N18                               |
| HIV infection                                      | B20                               |
| Pulmonary embolism                                 | I26                               |
| Other venous thromboembolism                       | I82                               |
| Renal Replacement Therapy                          | Z99.2                             |
| Mechanical ventilation                             | 5A19                              |
| Gastrointestinal bleeding                          | K92.0, 92.1, 92.2                  |
| Intracranial hemorrhage                            | I60-62                            |
| Ischemic stroke and TIA                            | G45, I63, I67                     |
| Composite outcome for thrombotic events            | G45, I63, I67, I74, I26, I81, I82, I21, I22 |
| Venous thromboembolism                             | I26, I81, I82                     |
| Myocardial infarction                              | I21, I22                          |

**LOINC**

| Test Description                        | Code(s)                                                                 |
|------------------------------------------|-------------------------------------------------------------------------|
| Positive testing for SARS-CoV2            | 9088, 94500-6, 94309-2, 94534-5, 94565-9, 94759-8, 94558-4, 94316-7, 94559-2, 96119-3, 95608-6, 94763-0, 94533-7, 94760-6, 94845-5, 96763-8, 95406-5, 94314-2, 96123-5, 97097-0, 94757-2, 95409-9, 94308-4, 94307-6 |
| Factor VIII activity in plasma            | 3209-4                                                                   |
| Positive testing for HIV                  | 56888-1, 7918-6                                                          |
| White (race)                              | 2106-3                                                                  |
| Black or African American                 | 2054-5                                                                  |

**CPT**

| Service Description                        | Code(s)                                                                 |
|--------------------------------------------|-------------------------------------------------------------------------|
| Hospitalization                            | 1013660, 1013659, 1013699 99221-99226; 99231-99233                      |
| Critical care services                     | 99291, 99292, 1013729, 1014309                                          |
| Renal replacement therapy                  | 90945, 90947, 90935, 90937, 90940, 36800                               |
Statistical methods

Descriptive statistics were presented as mean and standard deviation or percentages. The TriNetX platform was used to perform 1:1 propensity score matching with the use of logistic regression. Outcome analysis was performed before and after propensity score matching. Kaplan-Meier curves and log-rank tests were used to investigate the differences in all-cause mortality between groups. Risk Ratios (RR) with 95% confidence intervals (CI) for 30-day outcomes were calculated for each outcome. A p-value of <0.05 was considered statistically significant. All statistical analyses were conducted on the TriNetX platform.

Results

Baseline demographic and clinical characteristics

We identified 1,758 patients with pre-existing hemophilia A diagnosis prior to COVID-19 diagnosis (mean age 51.3 years; 73.1% white) and 5,191,908 comparators (mean age 49.7 years; 55.2% white). Among the patients without hemophilia A, 5,191,102 patients were included in the statistical analysis. Patients with hemophilia A had higher rates of comorbidities (Table 2). In relation to this, patients with anticoagulation and antiplatelet use were higher in the hemophilia group (20% vs. 7% and 15% vs. 7%, respectively).
|                                | Before matching                  | After matching                  |      |      |
|--------------------------------|----------------------------------|----------------------------------|------|------|
|                                | hemophilia cohort (n=1,758)      | non-hemophilia cohort (n=5,191,908) | p-value | S. Diff |
|                                | hemophilia cohort (n=1,758)      | non-hemophilia cohort (n=1,758)  | p-value | S. Diff |
| Demographics                   |                                  |                                  |      |      |
| Age (years)                    | 51.3 ± 19.8                      | 49.7 ± 19                        | 0.0004 | 0.0824 |
| White (%)                      | 73.1%                            | 55.2%                            | < 0.0001 | 0.3811 |
| Black or African American (%)  | 12.5%                            | 13.1%                            | 0.4518 | 0.0181 |
| Comorbidities                  |                                  |                                  |      |      |
| Hypertension (%)               | 52.2%                            | 24.0%                            | < 0.0001 | 0.607  |
| Diabetes mellitus (%)          | 24.6%                            | 11.1%                            | < 0.0001 | 0.3577 |
| Nicotine dependence (%)        | 26.1%                            | 9.5%                             | < 0.0001 | 0.4458 |
| Overweight and obesity (%)     | 23.6%                            | 10.7%                            | < 0.0001 | 0.346  |
| Ischemic heart disease (%)     | 27.0%                            | 9.9%                             | < 0.0001 | 0.4517 |
| Peripheral vascular disease (%)| 9.8%                             | 2.8%                             | < 0.0001 | 0.2885 |
| Heart failure                  | 17.9%                            | 4.7%                             | < 0.0001 | 0.4288 |
| Atrial fibrillation            | 11.0%                            | 5.2%                             | < 0.0001 | 0.2169 |
| Cerebrovascular disease (%)    | 24.1%                            | 5.3%                             | < 0.0001 | 0.5507 |
| CLRD (%)                       | 32.4%                            | 10.8%                            | < 0.0001 | 0.545  |
| VTE, excluding PE (%)          | 12.5%                            | 2.2%                             | < 0.0001 | 0.4041 |
| PE %                           | 6.1%                             | 1.0%                             | < 0.0001 | 0.2781 |
| Chronic kidney disease (%)     | 15.9%                            | 5.8%                             | < 0.0001 | 0.3303 |
| Liver disease (%)              | 31.6%                            | 4.9%                             | < 0.0001 | 0.735  |
| Alcohol related disorders (%)  | 11.4%                            | 4.1%                             | < 0.0001 | 0.2771 |
| HIV infection (%)              | 13.1%                            | 0.7%                             | < 0.0001 | 0.5037 |

**TABLE 2: Baseline characteristics of the patients**

Values are the number (%) of patients. S. Diff = standardized difference; BMI = body mass index; VTE = venous thromboembolism; PE = Pulmonary embolism; CLRD: chronic lower respiratory tract disease.
Outcome analysis

Before matching, there was no difference in all-cause mortality between the two groups (HR 1.027; 95% CI 0.688-1.533; p=0.682). Both groups had similar rates of composite outcome, severe COVID-19, and mechanical ventilation. Patients with hemophilia A were more likely to be hospitalized and require ICU level of care within 30 days after infection. Composite thrombotic events, venous thromboembolism and ischemic cerebrovascular events were significantly more frequent in patients with hemophilia A. Additionally, higher rates of gastrointestinal bleeding and ICH were observed in patients with hemophilia A.

After propensity score matching, there were 1,758 patients included in each cohort (Figure 1). Both groups were well-balanced on demographics and comorbidities. All-cause mortality was comparable between the two groups (HR 0.805; 95% CI 0.467-1.389). Patients in the hemophilia group and comparators had similar rates of severe COVID-19 infection (RR 0.85; 95% CI 0.612-1.184). Patients with hemophilia A were hospitalized more frequently than those without a history of hemophilia A (RR 1.34; 95% CI 1.151-1.55), but the rates of ICU admission were comparable between groups. No differences between groups were seen in venous thromboembolism, composite thrombotic events, myocardial infarction, and ischemic cerebrovascular events. GI bleeding and composite bleeding events occurred more frequently in patients with hemophilia A (RR 1.50; 95% CI 1.000-2.249 and RR 1.45 95% CI 1.013-2.073, respectively). The results are presented in Table 3.

FIGURE 1: Patient flow diagram
### TABLE 3: Outcomes at 30 days following COVID-19 diagnosis among patients with hemophilia A compared to patients without hemophilia A

Except where indicated otherwise, values are the number (%) of patients. RR = relative risk; 95% CI = 95% confidence interval. *statistically significant outcome; AKI: acute kidney injury; RRT: renal replacement therapy.

| Event                              | Before matching hemophilia cohort (n=1,758) | Before matching non-hemophilia cohort (n=5,191,102) | RR (95% CI) | After matching hemophilia cohort (n=1,758) | After matching non-hemophilia cohort (n=1,758) | RR (95% CI) |
|------------------------------------|--------------------------------------------|----------------------------------------------------|-------------|--------------------------------------------|------------------------------------------------|-------------|
| All-cause mortality                | 24 (1.4%)                                  | 53,802 (1.0%)                                      | 1.31 (0.885, 1.960) | 24 (1.4%)                                  | 28 (1.6%)                                      | 0.86 (0.499, 1.473) |
| Severe infection                   | 63 (3.6%)                                  | 140,711 (2.7%)                                     | 1.32 (1.038, 1.685)* | 63 (3.6%)                                  | 74 (4.2%)                                      | 0.85 (0.612, 1.184) |
| ICU admission                      | 41 (2.3%)                                  | 86,847 (1.7%)                                      | 1.39 (1.030, 1.887)* | 41 (2.3%)                                  | 51 (2.9%)                                      | 0.80 (0.536, 1.206) |
| Hospitalization                    | 338 (19.2%)                                | 448,739 (8.6%)                                     | 2.23 (2.021, 2.448)* | 338 (19.2%)                                | 253 (14.4%)                                    | 1.34 (1.151, 1.551)* |
| Mechanical ventilation             | 22 (1.3%)                                  | 55,575 (1.1%)                                      | 1.17 (0.772, 1.771) | 22 (1.3%)                                  | 25 (1.4%)                                      | 0.88 (0.498, 1.555) |
| Composite thrombotic events        | 122 (6.9%)                                 | 164,406 (3.2%)                                     | 2.19 (1.847, 2.601)* | 122 (6.9%)                                 | 127 (7.2%)                                     | 0.96 (0.756, 1.221) |
| Ischemic cerebrovascular events    | 45 (2.6%)                                  | 64,522 (1.2%)                                      | 2.06 (1.544, 2.749)* | 45 (2.6%)                                  | 48 (2.7%)                                      | 0.94 (0.628, 1.400) |
| Venous thromboembolism             | 74 (4.2%)                                  | 60,864 (1.2%)                                      | 3.59 (2.873, 4.489)* | 74 (4.2%)                                  | 72 (4.1%)                                      | 1.03 (0.748, 1.412) |
| Myocardial infarction              | 24 (1.4%)                                  | 49,185 (0.9%)                                      | 1.44 (0.968, 2.144) | 24 (1.4%)                                  | 28 (1.6%)                                      | 0.86 (0.499, 1.473) |
| Intracranial hemorrhage            | 15 (0.9%)                                  | 18,293 (0.04%)                                     | 2.42 (1.463, 4.009)* | 15 (0.9%)                                  | 13 (0.7%)                                      | 1.15 (0.551, 2.418) |
| Gastrointestinal bleeding          | 57 (3.2%)                                  | 40,335 (0.8%)                                      | 4.17 (3.232, 5.389)* | 57 (3.2%)                                  | 38 (2.2%)                                      | 1.50 (1.000, 2.249)* |
| Composite bleeding                 | 71 (4.0%)                                  | 57,732 (1.1%)                                      | 3.63 (2.892, 4.562)* | 71 (4.0%)                                  | 49 (2.8%)                                      | 1.45 (1.013, 2.073)* |
| AKI requiring RRT                  | 10 (0.6%)                                  | 13,038 (0.3%)                                      | 2.27 (1.221, 4.204)* | 10 (0.6%)                                  | 17 (1%)                                        | 0.59 (0.270, 1.281) |

**Discussion**

The COVID-19 pandemic has affected more than 600 million people worldwide to date [11]. One of the hallmarks of COVID-19 infection is coagulopathy, which is associated with increased morbidity and mortality [12]. The pathophysiology of COVID-19 coagulopathy is complex and not yet fully elucidated. Studies have shown that endothelial cell dysfunction, coagulation activation, and dysregulated fibrinolytic system play a major role in the pathogenesis of CAC [2,13]. Elevated factor VIII levels have been consistently observed in patients with COVID-19 and are a predictor of severity and mortality in COVID-19 patients [4,6]. Routine pharmacologic thromboprophylaxis is associated with improved outcomes in COVID-19, including mortality, and is recommended for hospitalized patients [14]. This poses a unique challenge, particularly for those with bleeding disorders requiring admission to the hospital due to inherent increased bleeding risk.

Studies have shown that the COVID-19 pandemic had a negative impact on lifestyle behaviors, routine care, and replacement therapies in patients with CBD [15-18]. However, there are only a limited number of clinical studies that have investigated the outcomes of COVID-19 in patients with bleeding disorders, and it is not known whether patients with bleeding disorders are more or less prone to the severe form of...
infection. Álvarez Román et al. investigated the outcomes of COVID-19 in 42 patients with CBD [7]. The majority of the patients had hemophilia A and were on prophylactic treatment. All patients who became infected with SARS-CoV-2 had mild disease, with none requiring specific treatment for infection. Another retrospective study reported outcomes of COVID-19 in nine patients with CBDs, of whom most had severe hemophilia. Among the nine patients, only one patient had severe disease, two experienced bleeding, and one experienced thrombosis [9]. Another retrospective, cross-sectional study from Iran, investigated the prevalence and outcome of COVID-19 in patients with CBD. They included nine patients with CBDs who had COVID-19. Only three patients required hospital admission, and there was no death [8].

Our results show that patients with hemophilia A were likely to have a severe infection, thrombotic complications, and bleeding events. However, patients with hemophilia A had a higher prevalence of comorbidities that were associated with severe COVID-19. Certain cardiovascular risk factors, such as hypertension as well as HIV and viral hepatitis infections were more prevalent in hemophilia patients in comparison with patients without hemophilia [19-22]. Therefore, to minimize bias, the baseline characteristics between the two groups were balanced using the propensity score-matched analysis. After matching, the rates of all-cause mortality, severe infection, or thrombotic events did not differ between the groups. We have shown that patients with hemophilia A were hospitalized more frequently compared to the general population. The reason for higher rates of hospitalization is unclear, but increased prevalence and risk of bleeding as well as physicians’ preference are potential causes. Although the rates of severe disease were similar in our study, the definition of severe COVID-19 varies across guidelines and institutions [23,24]. Hence, we acknowledge that the difference in the hospitalization rate might still have been due to the higher prevalence of severe COVID-19 in patients with hemophilia A.

We also showed that patients with hemophilia A had significantly more GI bleeding and composite bleeding events within 30 days after infection. Patients with hemophilia A have an increased risk of developing severe bleeding compared to the general population, and anticoagulation further increases the risk of bleeding. However, there is only limited evidence about the outcomes of prophylactic anticoagulation in hemophilia patients with COVID-19, and the impact of anticoagulation in patients with bleeding disorders needs to be addressed in further studies.

Limitations
The limitations of our study include retrospective design and the utilization of large datasets which potentially includes missing data. However, the TriNetX database has been shown to be reliable and have referential integrity [25]. Additionally, because of the reliance on diagnostic and procedure codes in data extraction, outcomes in different severity of hemophilia A were not evaluated. We excluded females because the majority of female patients are asymptomatic carriers and likely to carry the same ICD-10 codes as patients with hemophilia A, which would lead to bias.

It is important to note that the current study did not evaluate the impact of treatments for COVID-19. Thromboprophylaxis, corticosteroids, and antiviral therapies have been shown to improve disease-related outcomes in patients with COVID-19 [26]. Hence, differences in treatments between the groups may influence the outcomes. Additional research with individual patient data is required to address the impact of COVID-19-directed therapies in patients with bleeding disorders.

Conclusions
Our findings show that the mortality rate due to COVID-19 in individuals with hemophilia A is comparable to the general population. Additionally, patients with hemophilia A were not at higher risk for severe infection and thromboembolic events. However, patients with hemophilia A had higher rates of hospitalization and bleeding. Further research is warranted to fully characterize risks.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Gómez CA, Sun CK, Tsai IT, et al.: Mortality and risk factors associated with pulmonary embolism in coronavirus disease 2019 patients: a systematic review and meta-analysis. Sci Rep. 2021, 11:16025. 10.1038/s41598-021-95512-7
2. See JW, Kim DY, Yun N, Kim DM: Coronavirus disease 2019-associated coagulopathy. Microorganisms. 2022, 10.1038/s41596-021-00333-5

3. Lichter Y, Badelchayov T, Shavey I, et al.: Low FXIII activity levels in intensive care unit hospitalized COVID-19 patients. Thromb J. 2021, 19:79. 10.1186/s12979-021-00533-5

4. Tahatabai A, Rahin J, Menaker J, et al.: Factor VIII and functional protein c activity in critically ill patients with coronavirus disease 2019: a case series. A A Pract. 2020, 14:e01256. 10.1215/XXA.0000000000001256

5. De Cristofaro R, Liuzgo G, Sacco M, Lancellotti S, Pedicino D, Andreotti F: Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2 positive, but not severe acute respiratory syndrome coronavirus-2 negative, pneumonia: a case-control study. Blood Coagul Fibrinolysis. 2021, 32:285-9. 10.1097/MBC.0000000000009996

6. Abd El-Lateef AE, Alghamdi S, Elhid G, Khalil K, Kabrah S, Abdel Ghafar MT: Coagulation profile in COVID-19 patients and its relation to disease severity and overall survival: a single-center study. Br J Biomed Sci. 2022, 79:10098. 10.3389/bjbs.2022.10098

7. Álvarez Román MT, Butta Coll N, García Barcenilla S, et al.: Registry of patients with congenital bleeding disorders and COVID-19 in Madrid. Haemophilia. 2020, 26:773-8. 10.1111/hae.14089

8. Karimi M, Haghpanah S, Shahravani A: Prevalence and clinical features of COVID-19 in Iranian patients with congenital coagulation disorders. Blood Transfus. 2020, 18:415-4. 10.2450/2020.0225-20

9. Dorgalaleh A, Dabbagh A, Tabibian S, et al.: Patients with congenital bleeding disorders appear to be less severely affected by SARS-CoV-2: is inherited hypocoagulability overcoming acquired hypercoagulability of coronavirus disease 2019 (COVID-19) in? Semin Thromb Hemost. 2020, 46:855-5. 10.1055/s-0040-1713455

10. Topaloglu U, Palchuk MB: Using a federated network of real-world data to optimize clinical trials operations. JCO Clin Cancer Inform. 2018, 2:1-10. 10.1200/CCI.17.00067

11. WHO Coronavirus (COVID-19) Dashboard. (2022). Accessed: October 9, 2022: https://covid19.who.int.

12. Rattinelli EM: COVID-19 concerns aggregate around platelets. Blood. 2020, 136:1211-3. 10.1182/blood.2020007805

13. Willems LH, Nagy M, Ten Cate H, et al.: Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19. Thromb Res. 2022, 209:106-14. 10.1016/j.thromres.2021.11.027

14. Schulman S, Hohlberg M, Spyropoulos AC, et al.: ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost. 2022, 20:2214-25. 10.1111/jth.15808

15. Volot F, Soudry-Faure A, Callegarin A, et al.: Impact of first COVID-19 lockdown on paediatric and adult haemophilia patients treated in a French Haemophilia Comprehensive Care Centre. Haemophilia. 2022, 28:462-71. 10.1111/hae.14526

16. Álvarez-Román MT, Kurnik K: Care for children with haemophilia during COVID-19: Data of the PedNet study group. Haemophilia. 2021, 27:e537-9. 10.1111/hae.14286

17. Martínez García MF, Benitez Hidalgo Ó, Álvarez-Martínez E, et al.: Organization of a reference haemophilia unit and its change of activity during the COVID-19 pandemic. Haemophilia. 2021, 27:e473-5. 10.1111/hae.14160

18. Dorgalaleh A, Tabibian S, Baghaipour MR, et al.: Challenges and concerns of patients with congenital bleeding disorders affected by coronavirus disease 2019. Blood Coagul Fibrinolysis. 2021, 32:200-5. 10.1097/MBC.000000000001019

19. Barnes RF, Pandey B, Sun HL, Jackson S, Kruse-Jarres R, Quon DV, von Drygalski A: Diabetes, hepatitis C and human immunodeficiency virus influence hypertension risk differently in cohorts of haemophilia patients, veterans and the general population. 2022. 10.1111/hae.14637

20. von Drygalski A, Kolarits NA, Bettencourt R, et al.: Prevalence and risk factors for hypertension in hemophilia. Hypertension. 2013, 62:209-15. 10.1161/HYPERTENSIONAHA.113.01174

21. Barnes RF, Cramer TJ, Sait AS, Kruse-Jarres R, Quon DV, von Drygalski A: The hypertension of hemophilia is not explained by the usual cardiovascular risk factors: results of a cohort study. Int J Hypertens. 2016, 2016:2014201. 10.1155/2016/2014201

22. Kamphuisen PW, ten Cate H: Cardiovascular risk in patients with hemophilia. Blood. 2014, 123:1297-501. 10.1182/blood-2013-11-453159

23. Berlin DA, Gulick RM, Martinez FJ: Severe Covid-19. N Engl J Med. 2020, 385:2451-60. 10.1056/NEJMcp2009575

24. Underlying medical conditions associated with higher risk for severe covid-19: information for healthcare professionals | CDC. (2022). Accessed: October 9, 2022: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html.

25. Topaloglu U, Palchuk MB: Using a federated network of real-world data to optimize clinical trials operations. JCO Clin Cancer Inform. 2018, 2:1-10. 10.1200/CCI.17.00067

26. Bhimraj A, Morgan RL, Shumaker AH, et al.: Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Infectious Diseases Society of America, Arlington; 2022.